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Abstract
Background: To evaluate the incidence of Acute Kidney Injury (AKI) during therapeutic hypothermia (TH) and
rewarming in comatose patients resuscitated from Cardiac Arrest (CA).
Methods: We have performed a pilot study of consecutive comatose patients resuscitated from CA and admitted
to our Intensive Care Unit (ICU) from January 2013 to March 2015. The surface cooling devices used were: 1) Arctic
Sun® 5000; 2) Blanketrol® III. Data obtained at baseline and during TH included: temperature trend and rate, serum
creatinine, interleukin 1-beta, interleukin 6 (IL-6), urinary Interleukin-18 (uIL-18), diuretic use, urine output, fluid
balance (FB). AKI was defined according to Kidney Diseases Improving Global Outcomes (KDIGO) criteria.
Results: Thirty-six patients were treated with TH out of 46 ICU admissions (78%). According to KDIGO classification,
21 (58%) had no evidence of AKI while 15 (41.7%) presented AKI during TH. In particular, the incidence of AKI was
2.8% at 24 h, 33.33% at 48 h and 30.6% at 72 h from the onset of cooling. Slower rewarming (above 600 min) was
associated with with a non-significant lower incidence of AKI and with a non-significant lower levels of IL-6 and
IL-18u. Only two patients required renal replacement therapy during TH (7.6%). Median cumulative FB was 2441
[437–4043] ml for all patients; 3140 [1421–4347] and 1332 [−131–3772] specifically for AKI and not-AKI patients.
Conclusions: The hypothermia treatment, if not well performed, could be a double-edged sword for kidneys:
whereas hypothermia may confer protection by reducing metabolism and oxygen consumption, rapid rewarming
could nullify benefits leading to a worsening of kidney function and AKI. Additional clinical studies are needed to
determine the optimal rewarming rate and strategy.
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Background
Cardiac Arrest (CA) and resuscitation are an example of
a whole-body Ischemia/Reperfusion (I/R) injury character-
ized by a multi-organ dysfunction and systemic activation
of the innate immune system causing a ‘sepsis-like syn-
drome’ [1, 2]. The restoration of spontaneous circulation
(ROSC) after prolonged, complete, whole-body ischemia is
an unnatural pathophysiological state created by successful
cardiopulmonary resuscitation (CPR) [1]. The complex
phase of resuscitation which begins when patients re-
gain spontaneous circulation after CA has been defined
by the International Liaison Committee on Resuscitation
(ILCOR) as “post–cardiac arrest syndrome” [1]. The ische-
mia and reperfusion during CA, resuscitation and post-
resuscitation phases can particularly affect the kidney: I/R
injury leads to damage of epithelial cells by increased
oxygen radical production [2] and peroxidation of lipids
[3, 4] but also to interstitial inflammation and intersti-
tial “micro-vasculopathy” that are involved in abnormal
repair processes including incomplete repair of tubular
cell and fibrosis development [4]. The cross-talk between
the kidney and peripheral immune system in humans after
whole-body I/R injury and the changes over time in the
inflammatory response are speculative [5] and aside from
cardiogenic shock limited information are available regard-
ing predisposing factors and outcome of acute kidney injury
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(AKI) after CA [6, 7]. Although therapeutic hypothermia
(TH), also termed targeted temperature management,
is an established intervention (ILCOR/American Heart
Associatio) used for neuroprotection [3, 4] though recent
data challenge the benefit of TH using target temperature
lower than 36 °C [8, 9]. The effect of TH on renal protec-
tion is uncertain and poorly investigated.
The purpose of this study was to investigate the effect
of TH on the development of AKI and on renal outcomes
in comatose patients resuscitated from CA and treated
with surface cooling techniques. We hypothesized that
TH could be a protective strategy against renal I/R injury
while the shift from hypo- to normothermia may cause
rewarming injury.
Methods
Study design
This was a single center observational study. The
Institutional Review Board approved the protocol and
written informed consent was obtained from the nearest
relatives. Data were collected prospectively on 36 patients
between January 2013 and March 2015.
Patients selection criteria
All patients admitted to the emergency department for
out-of-hospital CA and treated with TH in the intensive
care unit (ICU) with a standardized protocol [10] were
considered eligible for the study. Inclusion criteria were:
18 years or older post-cardiac arrest patients (asystole or
pulseless electrical activity or ventricular fibrillation or
non-perfusing ventricular tachycardia as initial rhythm)
and ST-segment elevation myocardial infarction. Exclusion
criteria were: time from ROSC to initiation of cooling >6 h;
body temperature below than 30 °C on admission; major
trauma; severe burns; major surgery less than 72 h; sepsis
and septic shock; active bleeding or known pre-existing co-
agulopathy; intracranial bleeding; pregnancy; aggressive
care. Patients were treated either by the Arctic Sun® or
standard cooling blankets Blanketrol® IIIas decided by the
treating physician. The time between collapse and start
of cooling was calculated based on data provided by the
paramedic team.
Patient management
In all patients, the resuscitation attempt followed the
European Resuscitation Council 2010 guidelines for
basic and advanced cardiac life support and post-
resuscitation care [11]. In conjunction with resuscita-
tion procedures, the patient was assessed for study in-
clusion. ROSC was defined as an organized rhythm and
palpable pulse sustained for at least 20 min. In pre-
hospital setting, infusion of ice-cold normal saline, the
use of cold packs or the trans-nasal cooling was permit-
ted and it was according to choose of the physician in-
volved in the first aid. If necessary, a coronary
angiogram and a percutaneous coronary intervention
were performed before the admission to ICU. Once the
patient fulfilled the inclusion criteria and in agreement
with our protocol, sedation, analgesia, and paralysis
were started with: a Propofol bolus of 2 mg/kg,
followed by continuous infusion (0.5–3 mg/Kg/h) or
Midazolam bolus of 0.03–0.04 mg/kg, followed by
Fig. 1 Patient enrollment flow chart
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continuous infusion (0.2 mg/kg/hr); continuous infu-
sion of Remifentanil (0.02–0.2 mcg/kg/min) and of
Cisatracurium continuous infusion of 1 mcg/kg/min.
Other treatments such as magnesium, fluids, and vaso-
pressors were left to the discretion of treating physi-
cians. All patients had a bladder temperature probe
inserted for a continuous measurement of core
temperature, which provides feedback to the cooling
devices, freely chosen by the physician involved in the
treatment. The cooling devices used were:
1) Blanketrol® III, a cold blanket wrapped around the
upper torso. Automatic control mode, designed to
limit the magnitude of the difference between the
bladder and circulating water temperature (gradient
modes), was set with a bladder temperature of 33 °C;
If the patient’s temperature was lower than the target
temperature, the device heated the circulating water to
the highest allowable water temperature (42 °C); on the
contrary, if the temperature was higher than the target
temperature, the device cooled the circulating water to
Table 1 Baseline demographic data, resuscitation details and comorbidities
Entire Cohort
n = 36
AKI
n = 15
No AKI
n = 21
p OR 95% CI
Gender 0.94 0.94 0.17–4.99
Male 29 (80.5%) 12 (80%) 17 (81%)
Female 7 (19.5%) 3 (20%) 4 (19%)
Age (yrs) 60.5 [53–72.5] 60 [52–77] 63 [54–67] 0.5 1.02 0.96–1.07
BMI 26 [23–28.7] 27.6 [23.2–29.4] 24.7 [23–27.8] 0.18 1.13 0.94–1.35
SOFA score 9 [8–11] 10 [8–11] 9 [8–11] 0.79 105 0.75–1.46
APACHE II score 24 [21–26] 26 [22–29] 24 [21–24] 0.04 1.25 1.02–1.55
Presenting Cardiac Rhythm 0.95 1.05 0.20–5.43
VF/VT 29 (81%) 12 (80%) 17 (81%)
PEA/Asystolia 7 (19%) 3 (20%) 4 (19%)
Prehospital cooling 11 (30.5%) 6 (40%) 5 (23.8%) 0.12 0.35 0.09–1.30
Re-arrest after ROSC 0.68 0.84 0.371.91
Shockable 11 (30.5%) 6 (40%) 5 (23.8%)
No-Shockable 1 (2.8%) 0 (0%) 1 (4.8%)
None re-arrest 24 (66.6%) 9 (60%) 15 (75%)
ECM 0.24 1.58 0.74–3.39
Trained 11 (30.6%) 3 (20%) 8 (38.1%)
Untrained 12 (33.3%) 5 (33.3%) 7 (33.3%)
Lukas 5 (13.9%) 3 (20%) 2 (9.5%)
Non performed 8 (22.2%) 4 (26.7%) 4 (19%)
Total Number Of Shock 3 [1.2–7] 3 [2–4] 3 [1–7] 0.39 086 0.61–1.21
Total Adrenaline Given (mg) 1 [0–3.75] 0 [0–3] 1 [0–4] 0.64 0.94 0.71–1.23
Total Amiodarone Given (mg) 0 [0–300] 0 [0–0] 0 [0–300] – – –
Comorbidities
Hypertension 14 (22.2%) 8 (38.1%) 6 (28.6%) 0.14 0.35 0.09–1.40
Previous Kidney Disease 0 (0%) 0 (0%) 0 (0%) – – –
Previous Cardiac Surgery 2 (5.5%) 2 (13.3%) 0 (0%) – – –
Coronary Artery Disease 24 (66.6%) 11 (73.3%) 13 (61.9%) 0.48 0.59 0.14–2.50
Insulin Required Diabetes 8 (22%) 7 (46.7%) 1 (4.7%) 0.01 0.05 0.005–0.48
COPD 3 (8.4%) 3 (20%) 0 (0%) – – –
All quantitative variables are presented as median value [IQR], while quantitative data as total number (%). The differences between AKI and No-AKI patients has
been tested through multivariate analysis
Abbreviations: BMI Body Mass Index, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, VF Ventricular
Fibrillation, VT Ventricular Tachycardia, PEA Pulseless Electrical Activity, ROSC Restoration Of Spontaneous Circulation, ECM External Cardiac Massage, COPD Chronic
Obstructive Pulmonary Disease, AKI Acute Kidney Injury
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the lowest allowable water temperature (4 °C) until the
achieving the body target temperature. The circulation
of the water without heating or cooling characterizes
the reach of the target temperature.
2) Arctic Sun® 5000, the cooling pads applied on the
back, chest and thighs. Automatic mode was set to a
target temperature of 33 °C, and the maximum
cooling rate was used. The decision of the cooling
device was performed by treating physician based on
his preference. Target temperature was achieved and
maintained for 24 h. At the end of the maintenance
phase, rewarming phase started with a target
temperature of 36 °C and with a rewarming rate
between 0.25–0.5 °C per hour. Once the patient’s
temperature reached 36 °C, the device was turned off.
Data collection and blood sampling
Demographic variables and pre-hospital data were col-
lected prospectively for all patients at the admission
utilizing the Utstein criteria. Hemodynamic parameters
and temperature were measured continuously. Data
obtained on admission and 6, 24, 48 and 72 h included:
temperature trend and rate, serum creatinine (sCr),
interleukin 6 (IL-6), interleukin 1-beta (IL-1beta), urinary
interleukin −18 (uIL-18), urine output, fluid balance.
AKI was defined according to Kidney Diseases Improving
Global Outcomes (KDIGO) criteria [12, 13]. Estimated
Glomerular Filtration Rate and urinary output criteria were
not used for AKI diagnosis and staging in this study. Base-
line sCr was calculated using the Modification of Diet in
Renal Disease (MDRD) equation (back-estimation). In par-
ticular, in absence of previous values, the baseline creatinine
has been calculated as follow: GFR(Glomerular Filtration
Rate) = (75/[186 × (age-0.203) × (0.742 if female) × (1.21 if
black)])-0.887). For each time point, sCr considered for AKI
diagnosis was corrected for fluid balance according to re-
cent evidence [14]. The Sequential Organ Failure
Assessment (SOFA) score was calculated using standard
methods. Quantitative determination of uIL-18 was per-
formed by Human Instant ELISA kit (eBioscience, San
Diego, CA, USA). Cytokines determinations were per-
formed according to manufacturer’s protocol and instruc-
tions. Optical density was read by using a VICTORX4
Multilabel Plate Reader (PerkinElmer Life Sciences, Wal-
tham, MA, USA) at 450 nm. The concentration values for
these molecules were calculated from standard curves, ac-
cording to the manufacturer’s protocols. All tests were per-
formed in triplicate.
Outcomes
The primary outcome was the development of AKI dur-
ing all treatment period in patients treated with either
one of the two cooling devices. The secondary outcomes
were: the evaluation of association between duration of
each phase of TH (i.e. cooling, hypothermia, rewarming)
and AKI; the variation of sCr, urine output, fluid balance
and serum cytokine during TH; the effects of rewarming
phase on development of AKI. The outcomes were
assessed by study personnel who were aware of the type
of external cooling assigned for the subject.
Statistical analysis
The Shapiro-Wilk test was used to test the data for
normality. The differences between AKI and not-AKI
patients were tested using Mann-Whitney-Wilcoxon
for continuous variables, according to the not-normal
distribution of data, and presented as median [I-III
interquartile]. Categorical variables were analyzed
using the chi-square test and given as a percentage.
Differences between AKI and not-AKI have also been
evaluated through univariate and multivariate analysis;
results are presented in tables as p values, Odds ratio
(OR) and 95% confidence interval (95% CI). A p value
less than 0.05 was considered for statistical
Fig. 2 Bladder temperature trend in the Artic Sun Group and Blanket Group within the first 72 h. Data are given as median values
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significance. Data were analyzed using STATA 12 soft-
ware (STATA corp, 490, Lakeway Drive College Sta-
tion, 77845, Texas, US).
Results
Baseline demographics
From January 2013 till March 2015, 36 patients with
successful CPR were treated by TH out of 46 ICU
admissions for CA (78%) to the Department of
Anesthesia and Intensive Care Medicine, San Bortolo
Hospital (Fig. 1) and followed for the development of
AKI during ICU stay (Table 1). Ten (28%) patients
were treated with Blanketroll III (Blanket Group), and
twenty-six (72%) patients were treated with the Arctic
Sun Cooling Machine (Artic Sun Group).
Temperature trend and duration of each treatment phase
At the initiation of cooling, the temperature dropped from
a median pre-treatment temperature of 35.6 [34.7–36] °C
for Artic Sun Group and 35.7 [35.1–36.1] °C for Blanket
Group, to respectively a median plateau value of 33 °C
and 33.1 °C. At 6 h, the target temperature of 33 °C was
reached in both groups.
At 24 h, the median temperature reached was 32.9
[32.7–33] °C in the Artic Sun Group and 33.3 [32.9–
33.5] °C in the Blanket Group. The median temperature
kept during the rewarming period was 36.5 [36–36.7] °C
in the Artic Sun Group and 37.5 [36.8–37.7] °C in the
other Group, respectively. The median temperature kept
during the normothermic period was 36.7 [36.2–37] °C
in the Artic Sun and 37.4 [37.2–37.8] °C in the other
Group (Fig. 2). The duration of each phase and the time
Table 2 Renal outcomes
Entire Cohort
n = 36
AKI
n = 15
No AKI
n = 21
p OR 95% CI
LVEF <35 14 (38%) 7 (46.7%) 7 (33.3%) 0.37 0.53 0.13–2.14
VIS
Admission 0 [0–5] 0 [0–0] 0 [0–0] 0.75 1.02 0.89–1.16
6 h 5.7 [0–16] 3.7 [0–8.9] 9.8 [0–16.6] 0.36 0.95 0.85–1.05
24 h 5.5 [2.1–11] 4 [2.4–6.5] 7 [2–12.3] 0.27 0.91 0.76–1.08
48 h 2 [0–8.9] 3.9 [0–11] 2.1 [0–7] 0.48 0.96 0.85–1.07
72 h 0 [0–5.7] 2.3 [0–6.8] 0 [0–5] 0.15 1.25 0.92–1.72
MAP
Admission 86 [70–109] 84 [67–112] 89 [71–109] 0.26 0.97 0.93–1.02
6 h 84 [70–100] 82 [70–100] 85 [69–100] 0.56 1.02 0.95–1.09
24 h 83 [71–90] 79 [68–86] 84 [72–92] 0.59 0.98 0.91–105
48 h 82 [69–94] 88 [77–95] 78 [68–89] 0.37 1.03 0.97–1.09
72 h 84 [71–95] 74 [66–90] 92 [82–107] 0.06 0.95 0.89–1.00
Fluid Balance
24 h 333 [−434–1280] 448 [95–1250] 5 [−703–1477] 0.53 0.99 0.99–1.00
48 h 1522 [488–2236] 1290 [344–2621] 1592 [587–2099] 0.56 0.99 0.99–1.00
72 h 621 [−389–1749] 1155 [129–2168] 393 [−1567–1475] 0.67 0.99 0.99–1.00
Cumulative 2441 [437–4043] 314 [1421–4347] 1332 [−131–3772] 0.54 0.99 0.99–1.00
Urinary Output
24 h 2242 [1403–2844] 1890 [1100–2853] 2245 [1720–2820] 0.40 0.99 0.99–1.00
48 h 2877 [2362–3552] 2810 [2280–3400] 2990 [2400–3620] 0.19 1.00 0.99–1.00
72 h 3185 [2538–4060] 3010 [2370–4470] 3627 [2605–4040] 0.27 0.99 0.99–1.00
Ventilation days 8 [4–12.7] 6 [3–11] 8 [4–14] 0.94 0.99 0.93–1.07
ICU days 9 [4.5–12.5] 8 [4–12] 9 [4.5–14] 0.99 1.00 0.93–1.07
ICU mortality 23 (63.9%) 9 (60%) 14 (66.7%) 0.68 0.75 0.19–2.96
Hospital mortality 25 (69.4%) 10 (66.7%) 15 (71.4%) 0.99 1 0.93–1.08
90-days mortality 25 (69.4%) 10 (66.7%) 15 (71.4%) 0.99 1 0.93–1.08
Continuous variables are expressed as median [IQR], qualitative data as number (%)
Abbreviation: AKI acute kidney injury, ICU intensive care unit, LVEF Left ventricular ejection fraction, MAP mean arterial pressure, RRT renal replacement therapy, VIS
vasoactive inotropic score
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to fever, defined as the temperature above a threshold of
37.5 °C, is expressed in Table 2.
AKI development during TH treatment
According to KDIGO classification, among all 36 pa-
tients, 21(58%) had no evidence of AKI while 15(41.7%)
had AKI during TH. The incidence of AKI for each time
point is reported in Fig. 3.
In all population, the median time for rewarming was
600 [480–720] min. Although there is no statistically sig-
nificant difference, patients with AKI had a slightly in-
crease in rewarming time compared to patients without
AKI, respectively 540 [480–720] min vs 630 [480–720]
min (p = 0.13) (Table 3).
sCr, fluid balance, urine output, diuretic use and need of
renal replacement therapy (RRT) during TH treatment
Considering overall population, median values of sCr
based on MDRD formula was 1.06 [1.02–1.09] mg/dl)
while sCr at admission was 1.12 [0.94–1.22] mg/dl. These
values were: 0.82 [0.63–1.07], 1.04 [0.77–1.32], 1.06 [0.79–
1.42] mg/dl respectively at 24 h, 48 h, 72 h. sCr between
patients with AKI and no AKI is shown in Fig. 4.
Urine output increased from 24 h until to 72 h. The
average daily dose of frusemide was 20 [0–20] mg. N dif-
ferences have been observed for urinary output between
patients treated with or without diuretics at 24 h (p =
0.74), 48 h (p = 0.35) and 72 h (p = 0.23).
In overall population, the median fluid balance from
24 h to 72 h was +2441 [432–4044] ml. Only two patients
required RRT during the treatment (7.6%) (Table 2).
Cytokines concentration during the treatment period
For each time point, the plasmatic concentration of IL-6
and IL-1beta and the urinary concentration of uIL-18 have
been described for overall population and for AKI and no
AKI patients in Table 4. Figure 5 shows cytokines levels at
different timepoint in AKI and not-AKI patients with slow
rewarming (Panel A) and with rapid rewarming (Panel B).
Discussion
To the best of our knowledge, this is the first study sug-
gesting that the rewarming phase after TH applied to
post-CA patients may have an impact on the development
of AKI. During the TH period, among all 36 patients, 21
(58%) had no evidence of AKI according to KDIGO classi-
fication. AKI is a common occurrence, in particular from
Fig. 3 Incidence of AKI at different time points. From 24 h until 48 h there is an increase of AKI patients at KDIGO stage 1 and from 48 h until
72 h there an increase of patients at KDIGO stage 3
Table 3 Time duration of each treatment phase
Entire Cohort
n = 36
AKI
n = 15
No AKI
n = 21
p OR 95% CI
Time from CA to 33 °C 280.5 [240–385] 256.5 [216–325] 330.5 [254–390] 0.09 0.96 0.92–1.00
Time from TH induction to 33 °C 184.5 [120–248] 180 [120–210] 192 [120–252] 0.09 1.04 0.99–109
Time of TH duration 1440 [1440–1557] 1440 [1440–1620] 1440 [1440–1500] 0.33 0.99 0.97–1.00
Time from 33 °C to 36 °C 600 [480–720] 540 [480–720] 630 [480–720] 0.13 0.99 0.99–1.00
Time from 36 °C to fever 1380 [487–3180] 2880 [300–4320] 1260 [495–2880] 0.31 1.00 0.99–100
Median duration of treatment phases for all patients and specifically for AKI and no-AKI patients. All periods of time are expressed in minutes
Abbreviations: CA Cardiac Arrest, TH Therapeutic Hypothermia, AKI Acute Kidney Injury
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out-of-hospital-CA patients. Indeed, post-cardiac arrest is
characterized by a whole-body ischemia followed by reper-
fusion with activation of a systemic inflammatory response
and release of injury products into the circulation [5, 6]
responsible of additive stimuli for ischemic injury [15].
Following resuscitation from spontaneous CA, AKI is a
common complication with increased mortality risk,
dialysis requirement and prolonged hospital stay [7, 16,
17]. An intriguing field of research shows the capability of
a decrease in whole-body temperature to limit the ische-
mic injuries. Although TH has been used from 1950s to
protect the brain against a global ischemia after CA, there
is scant data on the potential benefit of this strategy on
kidney endpoints [18, 19]. Experimental studies
Fig. 4 sCr in patients with and without AKI at different time points. sCr levels progressively increases in AKI patients from 24 h until 72 h
conversely to non-AKI patients
Table 4 Cytokines trend in the two different groups of patients
Entire Cohort
n = 36
AKI
n = 15
No AKI
n = 21
p OR 95% CI
IL-6
Admission 79.05 [31.34–113.52] 82.79 [37.12–93.31] 62.32 [28.66–139.95] 0.28 0.99 0.98–1.00
6 h 56.9 [22.52–165.45] 36.50 [12.1–60.18] 64.96 [22.52–188.4] 0.62 0.99 0.99–1.00
12 h 53.58 [39.04–121.25] 45.17 [28.91–53.76] 63.88 [47.79–177.5] 0.38 0.99 0.99–1.00
24 h 46.75 [22.36–94.37] 46.46 [21.21–64.29] 46.75 [22.69–98.61] 0.80 0.99 0.98–1.00
48 h 44.38 [26.45–78.45] 57.83 [31.93–74.84] 40.63 [24.33–82.06] 0.69 1.00 0.99–1.01
72 h 48.89 [27.85–73.38] 43.47 [27.77–89.84] 48.91 [27.93–67.1] 0.24 1.00 0.99–1.02
IL-1beta
Admission 13.27 [11.3–20.41] 11.87 [10.87–15.2] 14.91 [12.3–23.22] 0.28 0.96 0.90–1.03
6 h 13.04 [9.93–16.48] 10.76 [9.58–13.98] 14.65 [11.52–20.43] 0.29 0.97 0.91–1.03
12 h 13.13 [11.71–16.54] 12.94 [10.52–20.33] 13.13 [12.34–14.92] 0.74 1.01 0.94–1.08
24 h 14.15 [11.85–21.92] 14.14 [11.43–18.76] 14.79 [11.96–21.92] 0.54 0.98 0.93–1.04
48 h 13.58 [11.62–17.52] 15.93 [11.21–19.01] 13.55 [11.62–16.63] 0.73 0.99 0.93–1.05
72 h 14.21 [11.64–22.27] 14.20 [10.56–17.22] 14.31 [11.64–49.43] 0.51 0.98 0.94–1.03
uIL-18
Admission 370.13 [319.63–740.5] 559.35 [369.76–997.36] 361.64 [309.94–412.06] 0.29 1.00 0.99–1.00
12 h 325.7 [299.6–375.5] 317.97 [262.60–345.89] 329.16 [303.16–375.9] 0.50 0.99 0.99–1.00
24 h 330.16 [280.93–365.5] 327.42 [288.01–361.53] 330.16 [219.25–373] 0.91 0.99 0.99–1.00
48 h 335.92 [289.68–393.47] 355.5 [301.5–566.52] 331.24 [277.84–365.5] 0.29 1.00 0.99–1.00
72 h 331.96 [207–439.37] 366.61 [331.92–845.5] 323.71 [130.05–405.5] 0.16 1.00 0.99–1.00
All cytokines concentrations are expressed in pg/ml and presented as median value [IQR]. The difference in cytokines concentrations at each time points has been
tested again the AKI development through multivariate analysis
Abbreviations: IL-6 Interleukin 6, IL-1beta Interleukin 1beta, uIL-18 urinary Interleukin 18, AKI, Acute Kidney Injury
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investigated the effect of body temperature on renal
susceptibility. On the basis of renal ischemic preserva-
tion by using low body temperature hypothermia,
Pelkey et al. demonstrated that minimal temperature
changes during renal ischemia alter functional and mor-
phologic outcome [20]. These findings in literature showed
that in animals hypothermia is able to reduce the risk of
renal failure after renal I/R injury [21, 22]. Renal function
is eventually depressed during hypothermia owing to a
fall in systemic blood pressure and the effect of
hypothermia on organ metabolism itself. As renal
blood flow progressively decreases, renal vascular resist-
ance rises, promoting a further decrease in renal flow and
a subsequent decrease in glomerular filtration. Increased
blood viscosity and vasoconstriction were both responsible
for this reduction of flow. In the setting of TH, this effect
is maintained for 24 h. In this hypothermic phase, from
admission to 24 h, there is a decrease of sCr probably due
to decrease in muscle metabolism. Clinical practice is
based on sCr measurements to monitor renal function
and classify AKI. For this reason, we used a validated cri-
teria to define and classified AKI: KDIGO. It is presumed
Fig. 5 Cytokines in patients with rewarming time below and above 600 min. 5 shows cytokines levels at different timepoint in AKI and not-AKI
patients with slow rewarming (Panel a) and with rapid rewarming (Panel b)
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that TH increases urine output particularly in the induc-
tion phase, this phenomenon is called cold-induced diur-
esis [23]. For this reason, we decide to not consider
urinary output criteria for diagnosis of AKI. Our results
suggested that in the rewarming phase, which started after
24 h, there is a slight increase of sCr associated with an in-
crease in urine output that did not correlate with diuretic
dose. Rewarming is a delicate phase of therapeutic
hypothermia. Similar to the brain [24], the rewarming
phase seems to be very important for the kidney and we
strongly believe that could be dangerous if it is not per-
formed slowly and with adequate time duration. Our re-
sults showed that with a rewarming time more than
600 min the risk of AKI is decreased. However, it does not
mean that longer rewarming times exclude any risk of
AKI. Rewarming of the patient is begun 24 h after the ini-
tiation of cooling. The literature recommends rewarming
slowly at a temperature of 0.3–0.5 °C every hour. It
means that rewarming will take approximately 8 h
[25]. Differences in the time of rewarming could im-
pact microinflammation and AKI risk.
In our study, patients who did not develop AKI had
median rewarming time of 630 min (10.5 h) whereas
those who did develop AKI had a median time of 540
(9 h). Rewarming is a delicate phase of TH. Adverse
consequences of rewarming on the whole body may ser-
iously limit the protective effects of hypothermia, leading
to secondary injury. In literature, previous studies showed
that the rise in body temperature accompanies a vasodila-
tion causing a rewarming shock and then careful fluid
monitoring during rewarming is crucial [26]. Probably,
controlled rewarming of 0.15 °C per hour should be rec-
ommended [27] Our data support this recommendation
showing less AKI with rewarming time > 600 min which
would translate to a rewarming rate of less than 0,4 °C/h.
It should be considered that in patients with severe
oliguria or anuria despite volume resuscitation, RRT
should be started before rewarming to avoid hyperkalemia
or metabolic acidosis due to transcellular electrolyte shifts
associated with this phase [28]. Hypothermia suppresses
ischemia-induced inflammatory reactions and release of
pro-inflammatory cytokines [29]. In our study, we assessed
inflammatory response dosing IL-6, IL-1beta and IL-18 and
results supported the evidence. In addition, uIL-18, a 22
KDa pro-inflammatory cytokine, produced by immune
cells, macrophages and proximal tubular cells, has a role in
inflammatory processes that exacerbate renal injury during
the extension phase of AKI [30, 31]. This cytokine is an
early biomarker for AKI in a variety of clinical scenarios in-
dicating the activation of inflammation in kidney [32–34].
Our results showed that with a rewarming time less than
600 min, there is a more increase in concentration respect
to those with a slower rewarming (above 600 min) support-
ing the hypothesis that rapid rewarming is associated with
increase risk of AKI (Table 4). The study has some limita-
tions. First, this is a single center trial with only a relative
small number of patients included. Secondly, the patients
were assigned to two different cooling methods in a non-
randomized fashion. Thus, a bias introduced by the cooling
method cannot be excluded. Our results, suggest possible
harm by an insufficiently controlled and or too short
rewarming period. As feasibility study, there was not a
comparison with a normothermic control group. The study
is too small to make conclusions about outcomes, although
the results are hypothesis generating.
Conclusions
The hypothermia treatment, if not well performed, could
be a double-edged sword for kidneys: whereas hypothermia
may confer protection by reducing metabolism and oxygen
consumption, rapid rewarming could nullify benefits
leading to a worsening of kidney function and AKI.
Additional clinical studies are needed to determine the
optimal rewarming rate and strategy.
Key messages
 In our prospective study, a rewarming time of more
than 600 min is associated to a decrease of the risk
of AKI;
 The uIL-18 levels has a role in inflammatory processes
that exacerbate renal injury during the extension
phase of AKI. During rewarming time less than 600
min, there is a more increase in concentration respect
to those with a slower rewarming (above 600 min)
supporting the hypothesis that rapid rewarming is
associated with increase risk of AKI.
 Whereas hypothermia may confer protection by
reducing metabolism and oxygen consumption,
rapid rewarming could nullify benefits leading to a
worsening of kidney function and AKI.
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